Company Kiora Pharmaceuticals, Inc.

Equities

KPRX

US49721T3095

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
0.47 ^USD	-2.08%		-4.14%	-10.03%

Mar. 25	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 09	HC Wainwright Adjusts Price Target on Kiora Pharmaceuticals to $2 From $3.50, Maintains Buy Rating	MT

Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of orphan retinal diseases. Its pipeline consists of three product candidates, including KIO-301, KIO-104, KIO-101 and KIO-201. Its lead product, KIO-301, is a vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). KIO-104 is a next generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH), which is being develop for the treatment of Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases, including rheumatoid arthritis, and as such is termed the Ocular Presentation of Rheumatoid Arthritis and Other Autoimmune Diseases (OPRA+).

Number of employees: 12

Managers	Title	Age	Since
Brian Strem CEO	Chief Executive Officer	44	21-07-25
Melissa Tosca DFI	Director of Finance/CFO	44	22-09-12
Stefan Sperl COO	Chief Operating Officer	-	-
Eric Daniels PRN	Corporate Officer/Principal	51	21-10-20

Members of the board	Title	Age	Since
Praveen Tyle CHM	Chairman	64	08-05-31
Carmine Stengone BRD	Director/Board Member	48	23-07-31
Aron Shapiro BRD	Director/Board Member	46	21-03-31
Kenneth Gayron BRD	Director/Board Member	54	21-03-31
David Hollander BRD	Director/Board Member	50	21-12-12
Brian Strem CEO	Chief Executive Officer	44	21-07-25
Erin Parsons BRD	Director/Board Member	48	22-01-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	26,256,197	26,029,992 ( 99.14 %)	0	99.14 %

Name	Equities	%	Valuation
Rosalind Advisors, Inc. 8.760 %	2,300,000	8.760 %	2 M $
AIGH Capital Management LLC 8.760 %	2,300,000	8.760 %	2 M $
The Lind Partners LLC 7.442 %	1,954,038	7.442 %	1 M $
Stonepine Capital Management LLC 6.856 %	1,800,000	6.856 %	1 M $
Lincoln Park Capital Fund LLC 0.4957 %	130,139	0.4957 %	91 878 $
Brian Strem 0.3927 %	103,100	0.3927 %	72 789 $
Citadel Securities GP LLC 0.3526 %	92,585	0.3526 %	65 365 $
Eric Daniels 0.3355 %	88,100	0.3355 %	62 199 $
CapFinancial Partners LLC 0.3047 %	80,000	0.3047 %	56 480 $
Geode Capital Management LLC 0.1417 %	37,211	0.1417 %	26 271 $

Kiora Pharmaceuticals, Inc.

332 Encinitas Boulevard Suite 102

92024, Encinitas

+858 224 9600

http://www.kiorapharma.com

address Kiora Pharmaceuticals, Inc.(KPRX)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.47 USD

Average target price

3.667 USD

Spread / Average Target

+680.14%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
KIORA PHARMACEUTICALS, INC.	-10.03%	12.34M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs